Filings
| Filing | Date | Type | Filed with |
|---|
| (688177)"Bio-Thera Solutions, Ltd."Announcement on Change of Accounting Firm | Nov 17, 2026 | Management or board change | Shanghai Stock Exchange |
|---|
| (688177)"Bio-Thera Solutions, Ltd."Notice on Convening the 4th Extraordinary General Meeting in 2026 | Nov 17, 2026 | Meeting notice | Shanghai Stock Exchange |
|---|
| (688177)"Bio-Thera Solutions, Ltd."Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2026 | Nov 14, 2026 | Meeting outcome | Shanghai Stock Exchange |
|---|
| (688177)"Bio-Thera Solutions, Ltd."Announcement on Obtaining a Drug Registration Certificate for Ashuli (Golimumab Injection) | Nov 6, 2026 | Operations update | Shanghai Stock Exchange |
|---|
| (688177)"Bio-Thera Solutions, Ltd."Announcement on Convening the Q3 2026 Performance Briefing | Nov 3, 2026 | Meeting notice | Shanghai Stock Exchange |
|---|
| (688177)"Bio-Thera Solutions, Ltd."Announcement on the Latest Business Development of BAT1706 (Bevacizumab) | Nov 3, 2026 | Other filings | Shanghai Stock Exchange |
|---|
| (688177)"Bio-Thera Solutions, Ltd."Report for Q3 2026 | Oct 28, 2026 | Quarterly report | Shanghai Stock Exchange |
|---|
| (688177)"Bio-Thera Solutions, Ltd."Notice on Convening the 3rd Extraordinary General Meeting in 2026 | Oct 28, 2026 | Meeting notice | Shanghai Stock Exchange |
|---|
| (688177)"Bio-Thera Solutions, Ltd."Announcement on Re-deliberation of Energy Management Agreements and Routine Related Party Transactions | Oct 28, 2026 | Material contract | Shanghai Stock Exchange |
|---|
| (688177)"Bio-Thera Solutions, Ltd."Announcement on Signing of Energy Management Agreement for Distributed Rooftop PV Power Station between Wholly-owned Subsidiary and Related Party, and Related Party Transaction | Oct 28, 2026 | Material contract | Shanghai Stock Exchange |
|---|
| (688177)"Bio-Thera Solutions, Ltd."Announcement on Obtaining the Drug Registration Certificate for BAT2306 (Secukinumab Injection) | Oct 23, 2026 | Operations update | Shanghai Stock Exchange |
|---|
| "Bio-Thera Solutions, Ltd."Announcement on Attending the 2026 Collective Reception Day for Investors in Guangdong Jurisdiction and Interim Performance Briefing for Listed Companies in the Jurisdiction | Sep 7, 2026 | Meeting notice | Shanghai Stock Exchange |
|---|
| "Bio-Thera Solutions, Ltd."Announcement on Resignation of the Chief Financial Officer and Designation of the Chairman and the General Manager to Act as the Chief Financial Officer | Sep 1, 2026 | Management or board change | Shanghai Stock Exchange |
|---|
| "Bio-Thera Solutions, Ltd."Special Report on the Deposit, Management and Actual Use of Raised Funds for the First Half of 2026 | Aug 25, 2026 | Other filings | Shanghai Stock Exchange |
|---|
| "Bio-Thera Solutions, Ltd."Announcement on Voluntary Disclosure of the Receipt of the Approval Notice for Supplementary Application for Bevacizumab Injection (POBEVCY) | Aug 20, 2026 | Other filings | Shanghai Stock Exchange |
|---|
| "Bio-Thera Solutions, Ltd."Announcement on Voluntary Disclosure Regarding the Progress of Receipt of Milestone Payment under the License and Commercialization Agreement with Intas Pharmaceuticals Ltd. for BAT2506 (Golimumab) Injection | Jul 29, 2026 | Other filings | Shanghai Stock Exchange |
|---|
| "Bio-Thera Solutions, Ltd."Announcement on Voluntary Disclosure of Semi-annual Performance Forecast for 2026 | Jul 28, 2026 | Guidance | Shanghai Stock Exchange |
|---|
| "Bio-Thera Solutions, Ltd."Announcement on Reply to Letter of Supervision and Inquiry on Information Disclosure of 2025 Annual Report | Jun 30, 2026 | Legal or regulatory action | Shanghai Stock Exchange |
|---|
| Announcement on the Status of the EU GMP Inspection at the Yonghe Facility | Jun 14, 2026 | Operations update | Shanghai Stock Exchange |
|---|
| Announcement on Voluntary Disclosure of Obtaining Marketing Authorization Approval of BAT2206 (Ustekinumab Injection) by Singapore HSA | Jun 10, 2026 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Obtaining Drug Registration Certificate for ICHALIG®/XICHALIG® (Ustekinumab Injection) | May 21, 2026 | Operations update | Shanghai Stock Exchange |
|---|
| Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of BAT8013 for Injection | May 12, 2026 | Operations update | Shanghai Stock Exchange |
|---|
| Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026 | Apr 30, 2026 | Meeting outcome | Shanghai Stock Exchange |
|---|
| Announcement on Loan Application Business of the Wholly-owned Subsidiary and the Company's Provision of Guarantee | Apr 27, 2026 | Financing | Shanghai Stock Exchange |
|---|
| Notice on Convening the 2nd Extraordinary General Meeting in 2026 | Apr 14, 2026 | Meeting notice | Shanghai Stock Exchange |
|---|
| Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of BAT3306 Combined with BAT8008 for Treatment for Advanced Solid Tumors | Apr 2, 2026 | Operations update | Shanghai Stock Exchange |
|---|
| Announcement on Voluntary Disclosure of Progress in Milestone Payment Received for Signing Authorization License and Progress in Commercialization Agreement with STADA for BAT2506 (Golimumab) Injection | Mar 26, 2026 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of BAT8008 Combined with BAT1006 and Trastuzumab of Advanced Solid Tumors | Mar 6, 2026 | Operations update | Shanghai Stock Exchange |
|---|
| Announcement on Voluntary Disclosure of Obtaining Marketing Authorization Approval of Usymro (Ustekinumab Injection) by UK MHRA | Mar 3, 2026 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Preliminary Earnings Estimate for 2025 | Feb 26, 2026 | Results | Shanghai Stock Exchange |
|---|
| Announcement on Acceptance of the Marketing Authorization Application for Batopoizumab Injection (BAT4406F) | Feb 24, 2026 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Marketing Authorization Approval of Gotenfia (Golimumab Injection) by European Medicines Agency (EMA) | Feb 12, 2026 | Operations update | Shanghai Stock Exchange |
|---|
| Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026 | Feb 6, 2026 | Meeting outcome | Shanghai Stock Exchange |
|---|
| Announcement on Voluntary Disclosure of Execution of a License, Manufacturing, Supply, and Commercialization Agreement with Avalon Pharma Regarding BAT3306 (Pembrolizumab) Injection | Feb 3, 2026 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Changing Sponsor Representative | Feb 2, 2026 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Expected Loss in Performance for 2025 | Jan 27, 2026 | Results | Shanghai Stock Exchange |
|---|
| Announcement on Return of Raised Funds Temporarily Used to Supplement Current Capital | Jan 22, 2026 | Financing | Shanghai Stock Exchange |
|---|
| Announcement on Signing a Project Construction Work Contract by the Wholly-owned Subsidiary and Related Party and Related Party Transactions | Jan 21, 2026 | Material contract | Shanghai Stock Exchange |
|---|
| Announcement on Voluntary Disclosure of Progress in Milestone Payment Received for Signing Authorization, Production, Supply and Commercialization Agreement with Gedeon Richter Plc. (Richter Gedeon) for BAT2206 (Ustekinumab) Injection | Jan 13, 2026 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Voluntary Disclosure of Milestone Payment Received for Signing Authorization License and Commercialization Agreement with Hikma Pharmaceuticals USA Inc. for BAT2206 (Ustekinumab) Injection | Jan 9, 2026 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Voluntary Disclosure of Progress in Milestone Payment Received for Signing Authorization License and Commercialization Agreement with Sandoz AG for BAT1706 (Bevacizumab) Injection | Dec 30, 2025 | Operations update | Shanghai Stock Exchange |
|---|
| Announcement on Estimated Daily Related Party Transactions in 2026 | Dec 29, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Obtaining Government Subsidies | Dec 22, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Acceptance of Marketing Authorization Application for Vilacita Monoclonal Antibody Injection (BAT5906) | Dec 18, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Convening the Q3 2025 Performance Briefing | Nov 12, 2025 | Meeting notice | Shanghai Stock Exchange |
|---|
| Report for Q3 2025 | Oct 28, 2025 | Quarterly report | Shanghai Stock Exchange |
|---|
| Announcement on Voluntary Disclosure of Progress in the Receipt of the Initial Payment from STADA for the Signing of the Licensing and Commercialization Agreement for BAT1806 (Tocilizumab) Injection | Oct 17, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on the Resignation of Core Technical Personnel | Sep 30, 2025 | Management or board change | Shanghai Stock Exchange |
|---|
| Announcement on Completing Industrial and Commercial Change Registration of Registered Address and Amending the Articles of Association | Sep 23, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Attending 2025 Online Collective Reception Day for Investors in Guangdong Jurisdiction | Sep 15, 2025 | Notification letter | Shanghai Stock Exchange |
|---|
| Announcement on Voluntary Disclosure of Progress in Milestone Payment Received for Signing Authorization License and Commercialization Agreement with Intas Pharmaceuticals Ltd. for BAT2506 (Golimumab) Injection | Sep 11, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Voluntary Disclosure of Obtaining Marketing Authorization Approval of Qletli (Adalimumab Solution for Injection) by UK MHRA | Sep 10, 2025 | Operations update | Shanghai Stock Exchange |
|---|
| Announcement on Convening the Semi-annual Collective Performance Briefing for Innovative Drug Industry on SSE STAR Market 2025 | Sep 5, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Notice on Convening the 2nd Extraordinary General Meeting in 2025 | Aug 29, 2025 | Meeting notice | Shanghai Stock Exchange |
|---|
| Announcement on Using Partial Idle Raised Funds to Temporarily Supplement Current Capital | Aug 20, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Result of Shareholding Reduction by Shareholder | Aug 19, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Return of Idle Raised Funds Temporarily Used to Supplement Current Capital | Aug 18, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of BAT1308 Injection Combined with BAT4706 Injection and BAT8008 for Injection for Treatment of Advanced Solid Tumors | Aug 7, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of Recombinant Anti-VEGF Humanized Monoclonal Antibody Injection (BAT5906) | Aug 1, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on the Change of Office Address and Contact Information of Investors | Jul 31, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Voluntary Disclosure of Semi-annual Earnings Preannouncement for 2025 | Jul 29, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of BAT4406F Injection | Jul 21, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Voluntary Disclosure of Signing Authorization License and Production, Supply and Commercialization Agreement with SteinCares for BAT2406 (Dupilumab) Injection | Jun 23, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on FDA Approval for BAT2206 (Ustekinumab) Injection in the United States | May 23, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Adjusting the Development Strategy of BAT3306 (Pembrolizumab) | May 22, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Completing the Term Change and Election of the Board of Directors and Appointment of Senior Management Members, Securities Affairs Representatives, and Head of Internal Audit | Apr 30, 2025 | Management or board change | Shanghai Stock Exchange |
|---|
| Report for Q1 2025 | Apr 28, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Share Reduction Plan for Shareholders | Apr 23, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of BAT7111 for Injection | Apr 21, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Election of Employee Representative Director for the Third Board of Directors | Apr 18, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Notice on Convening the 2024 Annual General Meeting | Apr 8, 2025 | Meeting notice | Shanghai Stock Exchange |
|---|
| Announcement on the Latest Development of BAT1806 (Tocilizumab) Business | Apr 1, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Voluntary Disclosure of Progress of Down-payment Received for Signing Authorization License and Commercialization Agreement with Intas Pharmaceuticals Ltd. for BAT2506 (Golimumab) Injection | Mar 31, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Resolution of the 18th Meeting of the 2nd Board of Supervisors | Mar 21, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Obtaining Acceptance of Application for Marketing Authorization of Golimumab Injection (BAT2506) | Mar 13, 2025 | Other filings | Shanghai Stock Exchange |
|---|